The small‐molecule imatinib (an ABL inhibitor) is the common treatment for chronic phase CML (Druker et al, 2001); however, resistances emerge mainly caused by point mutations in the kinase domain of BCR‐ABL that lower the inhibitor affinity. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.